Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting Pharvaris NV filings can be daunting—one press release about a trial pause can hide inside a 300-page 10-K, and pivotal Phase 3 updates often arrive as dense 8-Ks. If you have ever asked, “How do I find Pharvaris insider trading Form 4 transactions before the next data read-out?” this page is built for you.
Stock Titan’s AI reads each document the moment it hits EDGAR and surfaces what busy biotech investors need to see—cash runway tables, FDA feedback, and management stock moves. Whether you are searching for “Pharvaris quarterly earnings report 10-Q filing” to track R&D spend, or need “Pharvaris Form 4 insider transactions real-time” alerts to gauge executive conviction, every filing type is here and explained simply.
- 10-K & 10-Q: Understand trial timelines, dilution risk, and liquidity with our plain-English summaries—perfect for anyone Googling “Pharvaris annual report 10-K simplified.”
- 8-K material events explained: Rapid AI digests of clinical holds, fast-track designations, or equity offerings delivered as they post.
- Form 4 insider trading: Track “Pharvaris executive stock transactions Form 4” in real time and spot buying or selling patterns ahead of catalysts.
- Proxy statement executive compensation: Quickly see how milestone bonuses align with deucrictibant progress.
Stop scrolling through PDF after PDF. Stock Titan answers practical questions—“What does Pharvaris disclose about deucrictibant safety?” “How to read Pharvaris SEC documents with AI?”—so you can focus on decision-making, not deciphering biotech jargon.
Pharvaris N.V. filed a post-effective amendment to its Form F-3 registration statement to register an additional 6,045,155 ordinary shares (including 500,000 newly registered shares) for resale by a selling securityholder and updated the base prospectus and exhibits accordingly. The filing discloses clinical development progress for deucrictibant: the global Phase 3 RAPIDe-3 on-demand study (20 mg IR capsule) is enrolling with ~120 participants and topline data expected in Q4 2025, and the Phase 3 CHAPTER-3 prophylaxis study (40 mg/day XR) aims to enroll ~81 participants with topline data expected in H2 2026. The FDA previously lifted IND clinical holds after review of a 26-week rodent toxicology study.
Pharvaris N.V. filed a Form 6-K furnishing a Registration Rights Agreement dated
Pharvaris N.V. Schedule 13G/A discloses that a group of Venrock-related entities and two individuals beneficially own an aggregate of 2,047,620 ordinary shares of Pharvaris, representing 3.8% of the class as of June 30, 2025. The filing breaks this down as 380,109 shares held by Venrock Healthcare Capital Partners III, L.P., 38,028 by VHCP Co-Investment Holdings III, LLC, and 1,629,483 by Venrock Healthcare Capital Partners EG, L.P. The 3.8% percentage is calculated using 54,493,142 ordinary shares outstanding per the issuer's prospectus supplement dated July 22, 2025 (filed July 24, 2025). All entity filers are organized in Delaware; Nimish Shah and Bong Koh are U.S. citizens. The filing is signed on behalf of the reporting persons by Sherman G. Souther (authorized signatory) on August 14, 2025, and includes a certification that the securities were not acquired to influence control of the issuer.
FAQ
What is the current stock price of Pharvaris N.V. (PHVS)?
What is the market cap of Pharvaris N.V. (PHVS)?
